Metabolomics Market Seeks Major Boost with Government Support and Funding

According to the new market research report “Metabolomics Market by Product (GC,UPLC, CE, Surface based Mass Analysis), Application (Biomarker Discovery, Drug Discovery, Functional Genomics), Indication (Cardiology, Oncology, Inborn Errors), End User (Academic Institute, CROs) – Global Forecast to 2025″, published by MarketsandMarkets™, the global Metabolomics Technology Market size is projected to reach USD 4.1 billion by 2025, at a CAGR of 13.4% between 2020 and 2025.

Opportunity: Biomarker Development;

The metabolomics is used to identify new biomarkers through bioinformatics tools, which indicate the changes in the physiological state of a cell or tissue. Biomarkers are important for developing in-vitro diagnostic tools, environmental toxicology screening methods, and drug discovery and development techniques. The omics revolution of the last decade has increased the application of metabolomics in biomedical research.

As a result of these technological developments, new biomarkers are being regularly discovered. These biomarkers are required in medical sciences to better define and diagnose diseases, predict adverse drug events, and identify patient groups who would benefit from specific treatments. Moreover, in the near future, identifying biomarkers related to safety, sensitivity, and resistance to commercially available drugs will present significant growth opportunities for the metabolomics market.

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=900

Metabolomics Market
Metabolomics Market

North America accounted for the largest share of the metabolomics market in 2019.

Based on the region, the global Metabolomics Technology Market is segmented into North America, Europe, the Asia Pacific, Latin Ametica and Middle East & Africa. In 2019, North America accounted for the largest share of the metabolomics technologies market. The large share of the North America region can be attributed to the presence of major players operating in the market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.

The metabolomics market is dominated by a few globally established players such as Waters Corporation (US), Agilent Technologies (US), Shimadzu Corporation (Japan), Thermo Fisher Scientific (US), Danaher Corporation (US), Bruker Corporation (US), PerkinElmer (US), Merck KGaA (Germany), GE Healthcare (US), Hitachi High-Technologies Corporation (Japan), Human Metabolome Technologies, Inc. (Japan), LECO Corporation (US), Metabolon, Inc. (US), Bio-Rad Laboratories (US), Scion Instruments (US), DANI Instruments S.p.A. (Italy), GL Sciences (Japan), SRI Instruments (US), Kore Technology Ltd. (UK), and JASCO, Inc. (US) among others.

Request Sample Pageshttps://www.marketsandmarkets.com/requestsampleNew.asp?id=900

Biomarker Discovery accounted for the largest share of the metabolomics market

Based on application, the Metabolomics Technology Market has been segmented into biomarker discovery, drug discovery, toxicology testing, nutrigenomics, functional genomics, personalized medicine, and other applications. Biomarker discovery accounted for the largest share of the market in 2019. The growing implications of metabolic biomarkers to access the pathophysiological health status of patients are expected to drive market growth.

Academic and research institutes accounted for the largest share the metabolomics market in 2019

Based on end user, the Metabolomics Technology Market has been segmented into academic and research institutes, pharmaceutical & biotechnology companies, contract research organizations, and other end users. The academic and research institutes segment accounted for the largest share of the market in 2019. The increasing number of research activities in the field of metabolomics and funding to the academic and research institutes to conduct metabolomics research are the factors responsible for the largest share of the segment.

Speak to Analysthttps://www.marketsandmarkets.com/speaktoanalystNew.asp?id=900